When treating a child with a palatal abnormalityfor otitis media ora nasal obstruction, otolaryngologists ofte nface the question ofwhether the benefit s ofadenoidectomy are worth the risk of the development of velopharyngea l insufficiency. Treatment options fo r these patients include a complete adenoidec tomy, a partial adenoidectomy, or no surgical intervention . In this retrospective study, we describe the outcomes of22 such patients who were treated with a superior adenoidectomy performed with a St. Clair adenoid forceps under indirect vision with a laryngeal mirror. All patie nts expe rienced a complete or near-complete resolution of their nasal obstruction, and none developed permanent velopharyngea l insufficiency. Only three patie nts expe rienced a recurrence of otitis media. Our experience suggests that superio r adenoidectomy is a safe and effective procedure. +82% +109% Ref erences: I. Casale TB, Androde C , O u R. Safetyand eHicacy of once-doily lexofenadine HCI in the Irealmenl of aulumn seasonal allergiC rhinitis. Allerg y Aslhma Pr oc.
Introduction
The role of adenoidectomy has been well defined as a treatment modality for ch ildren who have recurrent acut e otitis media or persis tent chronic otitis media with effusion.' The procedure is also effec tive in relieving persistent nasal obstruct ion (with or without obstruc tive slee p apnea) and chronic sinusitis.' However, an adenoidectomy performed in a patient with a palatal abnormalitysuch as a short soft palate, a bifid uvula, or a submucosa l cleft palate-s-can cause velophary ngea l insufficie ncy.l? This problem has been recog nized for a long time, and otolary ngologists ofte n face a dilemma in tryi ng to decide whether the benefits of ade noidectomy are wort h the risks." Many authors reco mmend forgo ing adenoidectomy because of the risk of postoperative hypem asality.? When some form of surgica l intervention is necessary, many surgeons prefer to perform a partial adenoidectomy, but there is no co nsens us as to which type of ade noidectomy is best." One little-used procedure is a superior adenoidectomy performed with an aden otome. Thi s procedu re was first describ ed by Birrell" in 1966 and later by Shapiro." but since then it has been mentioned only occasionally.v'? In this paper, we retrospecti vely report the outco mes of 22 children with a high risk of velopharyngeal insuffic iency who underwent surgery wit h a modification of the technique described by Birrell. In these cases, a superior adenoidectomy was performed with a St. Clair forceps (fig ure) rather than with an adenotome.
Patients and methods
We reviewe d the records of all adeno idectomies performe d by or under the supervis ion of one ped iatric otolary ngo log ist (MMA) durin g a 13-month pe riod (Aug. I, 1994, through Aug . 3 1, 1995) . All procedures were performed at the University Hospital and Medica l Ce nte r at the State Uni versity of New York at Stony Brook . Dur ing that time, 164 childre n had undergone an ade noidectomy, with or with out a tonsillectom y. In addition to the information gleaned from presurgical and followup notes in the patient s' reco rds, followup outco mes data were obt ain ed from telephone surveys conducted in April 1996 .
In preparation for the surgery, all patien ts were placed under oro trac heal ge nera l anesthesia and were fitted with a Davis-Crowe mouth gag . T he hard and soft palates were exa mined by visual inspection and palpa tio n. The adequacy and length of the soft palate were assessed, and the soft palate was co nsidered to be short if its posterior border could not be made to reach the posterior pharyngea l wall when it was manually stretched intraoperatively. At this point, the information learned from this eval uation was com bined with the information obtained preo peratively, and the decision was then made to perform either a co mplete or partial ade noidectomy. A superior adenoi dectomy was performed on patients who had a short soft palate, a bifid uvula, a submucosal cleft palate, or preoperative ev ide nce of impaired palatal mobility.
Superior 1.7% Chronic Idiopathic Urt icaria Adverseeventsreported by patients12 yearsof age andolder inplacebo-control led chronic idiopathic urticaria stud ies were sim ilar to those reported in placebo-controlled seasonal allergic rhinitis studies. In pl acebocontrolled chronic idi opathic urt icaria cli nical trials, which incl uded 726 patients 12 years of age and . o l~e r receiving lexolenadinehydrochl oride tablets at dosesof 20 10240mg twice daily, adverse events were Similar in fexofenadine hydrochlori de andplacebo-treated patients. Table 3 lists adverse experiences in patients aged 12 years andolderwhichwere reported by greater than2% of patients treated wilh fexofenadinehydrochioride 60 mg tablets twice daily in controlled clinical studiesin the Uniled States and Canada and Ihal were more common with lexofenadine hydrochloride than placebo. Thesafety of fexofenadine hydrochl oride in thetreatmenl of chronic idiopathic urticaria in pediatric patients 6 to 11 year s 01ageis based on the safety profile of fexofenadine hydrochlorideinadultsandadolescent patients atdoses equal toorhigher thanthe reco mmended dose(see Pediatric Use). function, care should betaken indose selection , and ma y be useful to monitor renal function. (Se e CLINI CAL PHARMACOLOGY). ADVERSEREACTIO NS Seasonal Allergic Rhinitis Adults. In placebo-controlled seasonal allergic rhinitis clinical trials inpatients 12 years ofage and older, which included 2461 patients receiving fexofenadine hydrochloride capsules at doses of 20 mg10240mg Iwice daily, adverse eventswere similar infexofenadinehydrochloride and placebo-treated patients. All adverse events that were reported by greater than 1% of patients who received the recommended daily dose of fexofenadine hydrochloride (60mg capsulestwicedaily), andthat were more common withfexofenadine hydrochloridethan placebo, are listedin Table 1 .
In a placebo-controlledclini cal study in Ihe United states. whichincluded 570patie nts aged 12years and older receivingfexofenadinehydrochlori de tablets at doses of120 or 180 mgonce daily,adve rse eventswere similar in lexofenadine hydrochloride and placebo-treated patients. Table 1 also lists adverse expe riences thatwerereported bygreater than 2% of patients treated with fexofenadine hydrochlori de tablets at doses of 180 mgonce dailyandthai were morecommon with lexofenadine hydrochl oride than placebo. Ketoconazole (400 mg once daiiy) Thecha nges inplasma levelswerewi thin the rangeof pl asma levels achieved in adequateand well-controlled clini caltrials. The mechanism of these interaction s has beenevaluated in in vitro , in situ, and in vivo animal models. These studies indicate that ketoconazole orerythromycin co-ad mi nistration enhancesfexofenadinegastrointestinal abso rption. In vivo animal studies alsosuggest that in addition to increasing absorption, ketoconazole decreases fexofenadine hydrochlori de gastrointestinal secretion, while erythromycin may also decrease biliaryexc retion. Drug Interactions with Antac ids Administration of 120 mgof fexofenadine hydrochloride (2 x 60 mg caps ule) wit hi n 15 minutes of an aluminum and magnesium containi ng antacid ( 
Capsules and Ta blets
INDICA TIONSANDUSAG E Seasonal Allergic Rhinitis ALLEGRA isindicated for the reliefof sym ptoms associated with seasonal allergicrhinitis inadultsandchildren 6 years of age and older. Symptomstreated effectively were sneezing , rhinorrh ea, itchy nose/palate/throat, itchy/watery/red eyes.
Chroni cJJ liQjl athic Urt icaria ALLEG RA is indicated fortreatment of uncomplicatedski n manifestations of chronicidiopathic urti caria inadultsand children 6 yea rs ofage and older. It significantlyreduces pruritus and the number of wheals.
CD NTRAINDtCATIDN S ALLEGRA is contraindicated in patients with known hypersensitivity to anyof its ingredients.
PRECAUTIO NS Drug Interaction withErythromycin and Ketoconazole
Fexofenadinehydrochloride has been shown to exhi bit minimal (ca. 5%) meta boli sm. However, co-administration of fexofenadine hydrochloride with ketoconazole anderythromyci n led to increased plasma levels of fexofenad ine hydrochl ori de. Fexofenadine hydrochloridehadnoeffect onthepharmacokinetics of erythromycin andketoconazole. In two separate studies, Iexotenacine hydrochloride 120 mg twice daily (two timesIhe reco mmended twice dail y dose) was co-administeredwith erythromycin 500mgevery 8 hours or ketoconazole 400 mgonce dailyund ersteady-state conditionsto normal. healthy volunteers (n=24, each study). No differences in adverse events or aTe interval were observed when patie nts were administered texotenadine hydrochloride alone or in combination with erythromycin or ketoconazo le. The findings ofthese studies are summarized inthe following 
Germany) under indirect vision with a laryngeal mirror.
The open forceps were pressed against the upper portion of the adenoid, high in the nasopharynx. This was done first on the right side and then on the left, until both chonae and the posterior edge of the nasal septum were clearly visible. An oxymetazoline-soaked tonsil sponge was placed in the nasopharynx to promote hemostasis. After the sponge was removed, final hemostasis was achieved with a suction coagulator (Force2, Valleylab; Boulder, Colo.), and blood loss was measured. The nasal cavity and nasopharynx were then irrigated with normal saline administered with a 60-ml bulb syringe. An orogastric tube was passed to empty the stomach. Followup examinations were conducted at 4 weeks, 6 months, and I year after surgery, unless needed sooner.
Results
Between Aug . I, 1994, and Aug. 31, 1995, 164 patients underwent an adenoidectomy, with or without tonsillectomy, for nasal obstruction, obstructive sleep apnea, and/ or chronic or recurrent otitis media. All patients were under the care of the senior author (MMA). Twenty-two of these patients (13%), II of each sex, required a superior adenoidectomy. Their ages ranged from 3 to 10 years (mean : 5). The indications for adenoidectomy in general for these 22 children were chronic otitis media with effusion (n=IO), recurrent acute otitis media (n=4), and adenoid hypertrophy, mouth breathing, and snoring (n=21). In some patients, the latter group of symptoms was associated with obstructive sleep apnea (n=7), total nasal obstruction (n=2), and recurrent sinusitis (n= I). The indications for superior adenoidectomy were a short soft palate (n=14), bifid uvula (n=4), and questionable palatal mobility (n=4) .
The following associated features were noted in the patients who underwent a superior adenoidectomy: two previous myringotomies with tube insertions (n=2), asthma or dust allergy (n=3), heart murmur (ne l ), central perforation (n=I), cholesteatoma (ne l ), unilateral sensorineural hearing loss (n=I), and cerebral palsy and developmental delay (n=2). In addition, the following associated Volume 79, Number 4 procedures have been performed: tonsillectomy (n= 12), bilateral myringotomy with tubes (n= I I), bilateral myringotomy without tubes (n= I) , unilateral myringotomy (ne l ), frenectomy (rie l ), and a microscopic examination of the ear (cholesteatoma) (n= I).
During surgery, the estimated blood loss ranged from 6 to 60 ml (mean: 31). The high end of these estimates represents the cumulative blood loss in patients who required a cautery tonsillectomy. There were no primary or secondary hemorrhages.
Followup
One patient was lost to followup . During the immediate postoperative period, one patient had temporary nasal regurgitation, which resolved without any further treatment; this IO-year-old girl had undergone a tonsillectomy in addition to the superior adenoidectomy for obstructive sleep apnea. She had a short soft palate, but no bifid uvula or submucosal cleft palate .
All of the patients who underwent surgery for adenotonsillar hypertrophy that caused nasal symptom s or obstructive sleep apnea reported a complete or nearcomplete resolution of symptoms. Two patients who had undergone a myringotomy without tubes experienced recurrence of acute otitis media , although it was less frequent and less severe. Nonetheless, they both experienced a resolution of their obstructive symptoms. Another patient who had received two previous sets of tympanostomy tubes and who was under the care of an allergist required another (fourth) set of tympanostomy tubes 1 year after the superior adenoidectomy.
No patient developed hypernasality or permanent nasal regurgitation of fluids, and none required further adenoid intervention during the following year.
Discussion
The risk ofdeveloping velopharyngeal insufficiency subsequent to an adenoidectomy is well known. Gibb reviewed data on 27,734 children who had undergone tonsil and adenoid removal and found that only 19 had experienced subsequent hypernasality; 18 of them had some degree of a short soft palate, and five also had a bifid uvula. ' Calnan defined submucosal cleft palate as the triad of a bifid uvula, notching of the posterior border of the hard palate, and a muscular diastasis of the velum (zona pellucida)." Lubit described the prevalence of bifid uvula as I in 75. 12 Shprintzen etal performed nasopharyngoscopy on 25 patients with a bifid uvula and found that the musculus uvulae was absent in 19. 7 Of these 19 patients, I I had diastasis of the velurn. The authors concl uded that the presence of a bifid uvula raises the possibility that the patient has a submucosal cleft palate.
-Mason described the prognostic indicators of velopharyngeal insufficiency following adenoidectomy." These indicators include a submucosal defect of the hard palate, a short or thin velum, anterior dimpling of the velum, midline translucency of the velum, poor velar elevation, and the presence of a bifid uvula. He emphasized the importance of evaluating the point where the soft palate buckles during phonation in relation to the pharynx . The further forward the dimple on the elevated soft palate is, the less the effective length of the velum is . Calnan reported a series of what he called "congenital large pharynx" in patients who were also at increased risk for velopharyngeal insufficiency following adenoidectorny .' A list of such prognostic indicators is summarized in table 1. 5 Lateral adenoidectomy has been performed in an attempt to prevent velopharyngeal insufficiency in patients with an inadequate palate who require an adenoidectorny .' However, Masters et al reported that the removal of the lateral portions of the adenoids ("lateral bandectomy") was not effective in the treatment of hearing loss." Anterior partial adenoidectomy has also been suggested by Seid, although no data were mentioned in his report." Seid reported that nasopharyngoscopy was performed immediately prior to surgery. Adenoids were marked with methylene blue or other dyes trans nasally with a thin applicator in order to guide the surgeon in the selective removal of lymphoid tissue. Other authors have reported that a "medical adenoidectomy"-i .e., a short, intensive course of steroids-achieved a short-lasting 304 reduction in the size of adenoids." The use of gamma globulin injections to raise the general resistance was reported in the 1960s.1 5 Birrell described a modified adenoidectomy technique for patients in whom the competence of the palate was in doubt." He used an adenotome to selectively remove the upper portion of the adenoid. Hemostasis was achi eved with packing. Radiographs taken up to a year following surgery showed no evidence of any regrowth of the upper portion of the adenoid . Later, Shapiro described a series of 58 patients who were treated with es sentially the same superior adenoidectomy technique, and he reported excellent results, as no patient developed velopharyngeal insufficiency. " We have found that the use of the S1. Clair forceps with mirror control to perform a superior adenoidectomy provides for a more precise excision and avoids injury to the torus tubarius. In our experience, the success of superior adenoidectomy in patients with nasal obstruction is evident, as all patients experienced relief of the obstruction. Of the 14 patients who had chronic otitis media with effusion or recurrent acute otitis media, only three experienced a subsequent recurrence of otitis media.
There were no problems with bleeding in any of our patients. Although the conventional wisdom is that an incomplete adenoidectomy is associated with a higher risk of continued bleeding from the adenoid bed, the use of a suction coagulator with mirror control has helped prevent this problem.
Opponents of any form of adenoidectomy for patients with palatal abnormalities sometimes argue that these patients are at risk of developing velopharyngeal insufficiency at puberty. However, the de velopment of velopharyngeal insufficiency at puberty in the absence of a complete adenoidectomy or cleft palate is unu sual ." Children seem to compensate very well to a slow atrophy of . the adenoid, but not as well to the abrupt removal of the entire adenoid. One approach to treating children with palatal abnormalities and obstructive sleep apnea or snoring is summarized in table 2.
Why so many patients of a single otolaryngologist had their palate competence in doubt is an obvious concern. One explanation might be a selective referral pattern. Another factor to consider is that as the success of the procedure became clear, the surgeon (MMA) concluded that it was better to err on the side of conservatism and retain some adenoid tissue inferiorly when there was any question of palatal competence. This approach tak es into consideration the possibility that a revision procedure might be needed in the future to deal with the regrowth of the inferior adenoid tissue.
In conclusion, superior adenoidectomy with a S1. Clair forceps appears to be a safe and effective procedure. It should be considered when there is any question about palatal competence. Prospective studies that reported SUPERIOR ADENOIDECTOMY IN CHILDREN WITH PALATAL ABNORMALITIES Table 2 . Approach to ch ildren with palatal abnormalities and obstructive sleep apnea or snoring Exclud e or cor rect turb inate enlarg ements, chron ic rhinosinusitis, and lingual hypertrophy.
Exclude or correct neurolo gic disorders.
Con sider a tonsill ectomy.
Consider a mod ified uvulopalatopharynqoplasty, Con sider continuous positive airway pres sure.
Prescribe a "medi cal adenoide ctomy."
Perform an ante rior partial ade noidectomy, a superior adenoide ctomy, or a lateral adenoidectomy.
objec tive pre-and postoperative evaluations of velopharyngeal insufficiency would be helpful in further assess ing the usefulness of this procedure in selected cases .
